了解胆道癌症中同源重组修复缺陷:临床含义和与敏感性的相关性
I-A Mavroeidi1, J Burghofer2, S Kalbourtzis3
1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen; Division of Solid Tumor Translational Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
ESMO open
|July 17, 2024
概括
同类重组修复 (HRR) 基因的基因变异在27.5%的胆道癌症患者中被发现. 患有HRR基因突变的患者在一线化疗时显示出潜在的整体生存优势.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 癌症研究 癌症研究
背景情况:
- 胆道癌 (BTC) 是具有高死亡率和分子异质性的侵袭性癌症.
- 了解基因组变化对于BTC的向治疗至关重要.
研究的目的:
- 为了分子描述一组BTC患者,重点关注同类重组修复 (HRR) 基因变异.
- 在现实环境中评估HRR状态和临床结果之间的相关性.
主要方法:
- 从2016年到2023年对256名BTC患者的回顾性分析.
- 综合基因组分析,以评估HRR基因突变 (HRRm).
- HRRm状态与基化疗后的结果的相关性.
主要成果:
- 27.5%的患者患有HRRm,其中BAP1,ARID1A和ATM是最常见的突变.
- 患有HRRm的患者在一线白金化疗时显示出潜在的OS优势 (中位数为16.01vs15.68个月).
- 没有观察到与二线白金剂或以虹为基础的治疗方案的结果有显著差异.
结论:
- 在BTC中的HRRm可能会在一线白金化疗中产生生存益处,可能是由于可向的共同改变.
- 需要进一步的研究来确定HRR在BTC中的作用以及对制剂或PARP抑制剂的敏感性.
相关概念视频
Conservative Site-specific Recombination and Phase Variation
6.0K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


